J&J Q1 Sales Hurt By Generic Competition, Manufacturing Pause – NASDAQ

The company’s once-blockbuster antibiotic levofloxacin, marketed as Levaquin, had sales of over $1.5 billion in 2007. Since then, revenues have fallen dramatically and its patent expired in 2011. In the first quarter, the product generated a …

Leave a Reply

Your email address will not be published.

*